期刊文献+

海洋放线菌发酵物对肝癌细胞株生长和凋亡的影响 被引量:1

Effects of marine actinomycete fermented compound on the growth and apoptosis of HepG-2 cells in vitro
下载PDF
导出
摘要 目的研究一株南海海洋放线菌的发酵产物对肝癌细胞生长和凋亡的影响。方法采用MTT法评定海洋放线菌的发酵产物对肝癌细胞HepG-2增殖抑制作用及对正常细胞Vero细胞的细胞毒性,经Hoechst33258(8g/L)染色进行形态学观察,应用流式细胞术检测细胞周期、凋亡和凋亡基因Fas的表达情况。结果发酵物对HepG-2细胞的生长抑制效果明显,荧光显微镜下观察发现培养细胞中出现核固缩、凋亡小体;发酵物在诱导HepG-2细胞凋亡同时,下调Bcl-2表达水平,且均呈剂量效应关系。结论发酵物通过阻滞肿瘤细胞的生长及通过抑制Bcl-2诱导细胞凋亡等机制,对肝癌细胞的增殖有一定的抑制作用。 Objective To investigate the influence of Marine Actinomycete Fermented Compound on the growth and apoptosis of HepG -2 cells in vitro and its possible mechanism. Methods The inhibition of Fermented Compound on HepG -2 cells and normal cells(Vero) proliferation was detected by MTT method and disposed cells were stained with Hoechst 33258 ( 8 g/L). Cell apoptosis and expression of gene Bcl - 2 gene were further analyzed with flow cytometry.Results Fermented Compound significantly inhibited the growth of HepG -2 cells. The karyopycnosis and apoptotic body were observed under fluorescence microscope after ceils were freated with different concentrations of the Fermented Compound. Apoptotic peak and Bcl -2 expression were down regulated as measured by flow cytometry. Conclusion The inhibitory effect of Fermented Compound on HepG - 2 is related to induction of apoptosis by down - regulating Bcl - 2 expression.
出处 《广东医学》 CAS CSCD 北大核心 2009年第4期500-502,共3页 Guangdong Medical Journal
基金 广东省医学科研基金资助项目(编号:A2008342)
关键词 海洋放线菌 MTT 细胞凋亡 BCL-2 marine actinomycetes antiproliferative MTT method apoptosis Bcl - 2
  • 相关文献

参考文献9

  • 1李越中,陈琦.海洋微生物资源及其产生生物活性代谢产物的研究[J].生物工程进展,2000,20(5):28-31. 被引量:45
  • 2CARTE B K. Biomedical potential of marine natural products[ J]. Bioscience, 1996, 46(4) : 271 -286.
  • 3LAM K S. Discovery of novel metabolites from marine actinomycetes[ J]. Curr Opin Microbiol, 2006, 9 (3): 245- 251.
  • 4MOORE B S, KALAITZIS J A, XIANG Long - kuan. Exploiting marine actinomycete biosynthetic pathways for drug discovery[ J]. Antonie Van Leeuwenhoek, 2005, 87 ( 1 ) : 49 - 57.
  • 5HU W, KAVANAGH J J. Anticancer therapy targeting the apoptotic pathway[J]. Lancet Oncol, 2003, 4(12) : 721 -729.
  • 6ZOCCHI M R, POQQI A. PECAM - 1, apoptosis and CD34^+ precursors[J]. Leuk Lymphoma, 2004, 45(11) : 2 205 -2 213.
  • 7CHI K C, WALLIS A E, LEE C H, et al. Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel[ J ]. Oncologist, 2001,6 ( Suppl 3) : 40 - 44.
  • 8ZEITLIN B D, ZEITLIN I J, NOR J E. Expanding circle of inhibition : small - molecule inhibitors of Bcl - 2 as anticancer cell and antiangiogenic agents[ J]. J Clin Oncol, 2008, 26 (25) : 4 180 - 4 188.
  • 9佘妙容,郭坤元,陈锡林,牛新清.EGCG通过下调Bcl-2诱导KG1A白血病细胞凋亡[J].广东医学,2008,29(4):550-552. 被引量:3

二级参考文献21

  • 1Bao-He Zhu, Wen-Hua Zhan, Zheng-Rong Li, Zhao Wang, Yu-Long He, Jun-Sheng Peng, Shi-Rong Cai, Jin-Ping Ma, Chang-Hua Zhang, Department of Gastrointestinal & Pancreatic Surgery, First Affiliated Hospital, Sun Yat-Sen University,Gastric Center of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis[J].World Journal of Gastroenterology,2007,13(8):1162-1169. 被引量:30
  • 2[1]Kameyama,T.,et al(1987)J.Antibiol.,40:1664-1670
  • 3[2]Jansen,P.R.,Dweigt,R.,C.A.,and Fenical,W.(1991)Appl.Environ.Microbiol.,57:1102-1108
  • 4[3]Okami,Y.,et al(1976)J.Antibiot.,29:1019-1025.
  • 5[4]Okami,Y.,et al(1979)J.Antibiot.,32:964-966
  • 6[5]Takahashi,A.,et al(1989)J.Antibiot.,42:1556-1561
  • 7[6]Okazaki,Y.,Kitahara,T.,and Okami,Y.(1975)J.Antibiot.,28:176-184
  • 8[7]Pathirana,C.,et al(1991)Tetrahedron Lett.,32:2323-2326
  • 9[8]Fenical,W.and Jensen P.R.(1993)In:Marine Biotechnology,V(1):pharmaceutical and bioactive natural products pp.419-457,(eds.)David H.Attaway and Oskar R.Zaborsky,Plenum press,New York
  • 10[9]Umezawa,H,et al(1983)J.Antibiot.,36:471-477

共引文献46

同被引文献10

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部